Findings

What do systematic reviews say?

8 questions · 8 findings · 1 reviews · Kidney and Transplant

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 12.5%Moderate 5 · 62.5%High 2 · 25%

Death associated with CMV disease · solid organ transplant recipients

Ganciclovir showed no clear difference in death due to CMV disease compared with aciclovir (moderate certainty).

1 finding from 1 review

Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients 2024 · Cochrane Headline outcomes only
RR 0.33 [0.07, 1.58]
6 studies · 832 participants
Moderate

All‐cause death · solid organ transplant recipients

Ganciclovir showed no clear difference in all‐cause death compared with aciclovir (moderate certainty).

1 finding from 1 review

Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients 2024 · Cochrane Headline outcomes only
RR 1.13 [0.82, 1.58]
8 studies · 1138 participants
Moderate

Acute rejection · solid organ transplant recipients

Ganciclovir showed no clear difference in acute rejection compared with aciclovir (high certainty).

1 finding from 1 review

Graft loss · solid organ transplant recipients

Ganciclovir showed no clear difference in graft loss compared with aciclovir (moderate certainty).

1 finding from 1 review

Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients 2024 · Cochrane Headline outcomes only
RR 0.55 [0.27, 1.13]
3 studies · 268 participants
Moderate

Opportunistic infections: other viral infections · solid organ transplant recipients

Ganciclovir showed no clear difference in opportunistic infections: other viral infections compared with aciclovir (moderate certainty).

1 finding from 1 review

Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients 2024 · Cochrane Headline outcomes only
RR 0.81 [0.32, 2.01]
4 studies · 740 participants
Moderate

Leucopenia · solid organ transplant recipients

Ganciclovir may leads to higher leucopenia compared with aciclovir (low certainty).

1 finding from 1 review

Kidney dysfunction · solid organ transplant recipients

Ganciclovir showed no clear difference in kidney dysfunction compared with aciclovir (moderate certainty).

1 finding from 1 review

Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients 2024 · Cochrane Headline outcomes only
RR 0.96 [0.83, 1.1]
4 studies · 661 participants
Moderate

CMV disease · solid organ transplant recipients

Ganciclovir leads to lower CMV disease compared with aciclovir (high certainty).

1 finding from 1 review